Minimally Invasive, Tissue-Preserving Breast Augmentation: Insights From a Large Case Series, Technique and Surgical Pearls Authors: Troy A Pittman, Anna Steve, Kamakshi Zeidler, Jeremy R Chidester, M Bradley Calobrace Published: 2026 ABSTRACT AbstractBackgroundBreast augmentation rates have remained relatively stagnant due to ongoing concerns regarding implant safety, fear of an oversized aesthetic, and trepidation surrounding general anesthesia. Advances in understanding breast anatomy have enabled innovative techniques that enhance breast volume while preserving surrounding soft tissues. This study presents the initial US experience with a minimally invasive, tissue-preserving breast augmentation (MI-BA) technique utilizing atraumatic tunneling, balloon-assisted pocket creation, and sixth-generation silicone implants.ObjectivesThe aim of this study was to describe the authors’ early experience with an inframammary-based MI-BA, including its anatomical rationale, surgical technique, learning curve, early outcomes, satisfaction, and practical insights to guide broader adoption.MethodsA prospective multicenter analysis was performed across 5 surgical centers over a 6-month period. Patient demographics, implant characteristics, anesthesia modality, early complications, patient-reported recovery, and satisfaction scores were prospectively collected. 161 consecutive patients were enrolled across five sites, but 2 were removed from the analysis due to age, as they were implanted off-label. Of note, the 2 patients removed were highly satisfied and had no complications.ResultsIn total, 159 consecutive female patients underwent MI-BA, with 13% undergoing concomitant fat transfer and/or mastopexy. All patients received tumescent infiltration, 95% of procedures utilized a bolus anesthesia technique, with 58% performed under local anesthesia with sedation. No early postoperative hematomas, loss of breast sensation, sensory disturbances, or abnormal pain were reported. Surgeon satisfaction was high (96%), and most patients reported being satisfied or extremely satisfied (94%).ConclusionsThis early US experience demonstrates a minimally invasive, tissue-preserving approach to breast augmentation that leverages implant-specific technologies to enable procedures under local anesthesia, minimize soft-tissue trauma, and facilitate rapid recovery. Although early outcomes are favorable, continued long-term follow-up is underway and will be reported in future studies.Level of Evidence: 4 (Therapeutic) For image description, please refer to the figure legend and surrounding text. Breast augmentation remains one of the most popular aesthetic procedures performed in the United States, with nearly 306,000 procedures performed in 2024, a number that has modestly increased over the course of the last 10 years.1 It has been estimated that there are around 60 to 70 million breast implants in over 35 million patients worldwide.2 While the operative fundamentals and equipment to perform traditional breast augmentation have not changed significantly over the past 2 decades, improvements in surgical technique, a greater understanding of breast anatomy,3 and advances in device technology4 have led to the advent of minimally invasive options for breast augmentation.5 Over the last several years, there has been debate about the best choice for implant positioning in the breast. Traditional positions include: submuscular, subglandular, subfascial, and “dual-plane.”6 In the United States, the most common plane for implant placement remains under the muscle.7 However, given the popularity and rapid adoption of prepectoral breast reconstruction there has been interest in applying the same principles to aesthetic breast surgery.8 This interest has been potentiated by the introduction of sixth-generation implants with a 4-micron surface texture9 associated with low capsular contracture rates,10,11 leading many surgeons to transition to over-the-muscle/prepectoral implant placement in both primary and secondary breast augmentations.12,13 Given the concerns that over-the-muscle implant placement may carry a higher risk of capsular contracture and increased implant visibility,14,15 surgeons have advocated for subfascial placement over the subglandular plane. The “New” Breast Anatomy A complete review and deeper understanding of breast fascial anatomy provide new insights that question the superiority of traditional techniques (submuscular and over-the-muscle subfascial alike) and present a case for minimally invasive technologies to place implants in a new position, within the posterior lamella of the breast.16 The superficial fascial system of the breast was first depicted by Colles17 and Scarpa,18 and then described in greater detail by Lockwood.19 Rehnke et al further described the relationship between the superficial facial system of the breast and its relationship to the chest wall.3 In cadaveric dissection, a circumferential closed system of ligamentous fibers was identified that attach the deep superficial fascia of the breast to the pectoralis fascia via Cooper's ligaments, creating a 3-dimensional ring of adherence referred to as the circummammary ligament (CML). Breast parenchyma is enveloped between the superficial and deep layers of the superficial fascial system, creating an anterior and posterior lamella of the breast. Rehnke went on to describe a “subglandular space” that lies between the posterior lamella and the fascia of the pectoralis major muscle. The attachments of the posterior lamella to the pectoralis major muscle fascia in the periphery provide 180° coverage and support when an implant is placed in this plane (Figure 1—Superficial fascial system of the breast: saggital view. Used with permission by Robert Rehnke, MD and Susan Gilbert). Superficial fascial system: sagittal view. (Used with permission by Robert Rehnke, MD and Susan Gilbert.) Similar anatomic findings have been reported by other authors in the literature.20-22 Duncan et al performed a systematic literature review to define key anatomic structures of the breast and describe their significance, and similarly concluded that the superficial fascia encases the breast in a well-defined pocket along the breast periphery.23 However, due to subtle differences in anatomic descriptions and lack of alignment on nomenclature, a consensus on technique and the superiority of its implementation has not been reached. In a letter to the editor in 2020, Rehnke commented on Graf's initial subfascial research, stating: “The benefit of learning access to this dissection plane is great. It is the natural location of the corpus mammae but still outside of the gland. This means the projecting forces exerted by the implant are not resisted by the posterior lamina fascia (as they would be in a subglandular, subfascial, or submuscular placement). These risks entering the substance of the corpus mammae, which could lead to bacterial contamination in some instances. In addition, this approach eliminates the need for subpectoral, textured, anatomical implants, and the attendant concerns associated with them, such as chronic inflammatory capsules resulting from biofilm, and the associated cancer—breast implant-associated anaplastic large cell lymphoma.”24 Manuel Chacon-Quiros, a pioneer in breast tissue preservation research, has also applied these principles as they relate to mastopexy and mastopexy/augmentation.25 His technique involves preservation of ligamentous and fascial structures such as the breast lamellae and Cooper's ligaments to maintain long-term support with minimal disruption of the soft tissues, while completely sparing the chest wall musculature. Most recently, Lhuaire et al described a consistent posterior lamella composed of laminated adipose and fascial layers.16 Through a series of cadaver dissections, the group described an “intralamellar plane,” which separates the corpus mammae from the pectoralis major fascia. Histologic analysis of this plane with hematoxylin & eosin, Masson's trichome and Sirius Red/Fast Green staining shows that this tissue is devoid of breast tissue. The new appreciation for the complexity of the internal anatomy of the breast sets the stage for an advanced minimally invasive tissue-preserving breast augmentation (MI-BA) technique. Minimally Invasive, Tissue-Preserving Breast Augmentation The MI-BA technique is an inframammary-based, ligament-sparing approach to breast augmentation performed using specialized tools to create an implant pocket in the posterior intralamellar plane, behind the breast.5 The authors present early 6-month results from a large multicenter consecutive case series with the procedure. They also discuss the early experience learning curve with the technique, including key perioperative protocols for surgeons considering implementing MI-BA in their own practices. METHODS Study Design 161 consecutive patients were enrolled, but 2 were removed from the analysis due to age, as they were implanted off-label. Of note, the 2 patients removed were highly satisfied and had no complications. Patients were enrolled consecutively across 5 separate surgical centers over a 6-month period from August 2025 to February 2026 and underwent one of the following procedures: Primary MI-BA Primary MI-BA Primary MI-BA with fat transfer Primary MI-BA with fat transfer Primary MI-BA with mastopexy Primary MI-BA with mastopexy Devices Used The surgical devices used in all procedures are the Motiva Channel Separator and the Motiva Inflatable Balloon (Establishment Labs, Alajuela, Costa Rica) (Figure 2—Interoperative photograph of surgical set-up. Includes channel separator and balloon dissector x 2. Courtesy of Jeremy Chidester, MD). Interoperative photograph of surgical set-up. Includes channel separator and balloon dissector × 2. (Courtesy of Jeremy Chidester, MD.) The breast implants used in all cases were sixth-generation implants, comprised of a single-lumen silicone elastomer shell with a controlled surface architecture produced by a mandrel imprinting technique with an average roughness of 4 microns (Establishment Labs).10 The implants are filled with a highly viscoelastic silicone gel that elongates without deformation, and is a key characteristic that makes them suited for this technique—namely passing through a tunnel from the inframammary fold (IMF) through the CML.4 Given the observational nature of the study (nothing investigational or experimental), institutional review board approval was not obtained. All surgeons followed good clinical practices as outlined in the Declaration of Helsinki. All patients signed informed consent and the US Food and Drug Administration (FDA) informed-decision checklist, and all patient data were deidentified. Surgical Technique Markings The patient is marked preoperatively in the standing position. Key features include marking the sternal notch, the midline, the medial superior and inferior borders of the CML, a 1-cm cuff off these aesthetic lines to demarcate the thickness of the CML, and an inner circular marking that aligns with the base of the implant and aligns with the position of the inflatable balloon and the pocket created by it for the implant (Figure 3—Standard patient markings—minimally invasive breast augmentation—courtesy of Troy A. Pittman, MD, and Video 1, available online at https://doi.org/10.1093/asj/sjag113). Standard patient markings—minimally invasive breast augmentation. (Courtesy of Troy A. Pittman, MD.) Positioning The patient is placed supine on the operating table with the arms abducted at 90° and secured to arm boards. Incision A 3- to 4-cm incision is made at the 5 and 7 o’clock positions in the IMF. The incision is carried full thickness through the skin. Placement at the 5 and 7 o’clock position facilitates angulation of the channel separator toward the sternal notch, compared with a midline (6 o’clock) incision. This approach is particularly advantageous in postpartum patients with rib flaring and may also reduce bleeding because of the anatomical location relative to the irrigation plane.26 Infiltration Infiltration into the intralamellar plane is a key component of a successful procedure. The infiltration solution is comprised of a modified Klein solution containing lidocaine, epinephrine, bicarbonate, and tranexamic acid (Supplemental Figure 1, available online at https://doi.org/10.1093/asj/sjag113). Infiltration is done under ultrasound guidance (Video 2, available online at https://doi.org/10.1093/asj/sjag113). The infiltration cannula is advanced into the intralamellar space and ultrasound is used to visualize the cannula above the pectoralis muscle fascia and below the deep layer of the superficial fascia (the intralamellar plane) as the tumescent solution is infiltrated. Lifting the breast gland while advancing the infiltration cannula facilitates easier passage of the cannula. Tumescent solution is infused with either a bolus or a fanning technique, with most surgeons preferring a bolus technique because it requires only a single verification of cannula positioning and helps prevent creation of a false passage. For surgeons who are not comfortable using ultrasound, this plane can be identified under direct visualization. In this case, sharp dissection is carried out through the superficial and deep fascia at the IMF, and the posterior lamella is accessed with a spreading technique over the pectoralis muscle fascia. The tumescent cannula is then inserted with direct visualization of this plane. In primary augmentation, approximately 200 mL of tumescent solution is infiltrated per breast, whereas in mastopexy/augmentation, approximately 100 mL is infiltrated, to account for the lower capacity of the soft-tissue space with a mastopexy closure. Once the posterior intralamellar space is satisfactorily tumesced, the breasts are massaged to aid in fluid dispersion. Prospective hemostasis is achieved by allowing the tumescent solution to sit for 10 minutes to maximize the vasoconstrictive effect of epinephrine. Intralamellar Tunneling With the Channel Separator The channel separator, designed with an atraumatic tip, to be used in screwdriver fashion, is then passed through the inframammary incision toward the sternal notch, parallel to the chest wall, until the tip of the dissector reaches the superior aspect of the CML, creating a tunnel that allows the balloon dissector to fully advance. The plane of dissection is the same plane as the tumescent solution was infiltrated into, the posterior intralamellar plane. Following creation of the intralamellar tunnel, the channel separator is removed. A finger-swipe is used to confirm that the pectoralis muscle is below and that the breast gland is above, confirming the correct prepectoral plane of dissection. Balloon Inflation The inflatable balloon is placed into the newly created tunnel and inflated, creating a pocket within the posterior intralamellar plane. To retain optimal pocket position, the operating surgeon holds the handpiece of the balloon and the assistant fills with the pump, while the surgeon stabilizes the breast laterally to prevent overdissection. The balloon is filled in each case to a size commensurate with the width of the chosen implant to ensure a “nesting” effect of the soft tissue around the implant. For tight, dense, or more difficult to expand breasts, the balloon should be deflated and reinflated several times to further assist with pocket expansion. The balloon is clamped on the first side to hold its filled position while the procedure is completed on the contralateral side. This maneuver also maintains sustained pressure within the pocket, which may assist in minimizing bleeding (Figure 4—Placement of inflated balloon dissector—courtesy of Troy A. Pittman, MD). Placement of inflated balloon dissector. (Courtesy of Troy A. Pittman, MD.) Implant Deployment Following deflation and removal of the balloon, the tunnel at the IMF is dilated using the long ends of an army-navy retractor to allow space for implant delivery. The inflatable balloon can also be used to temporarily dilate the tunnel by inflating 2 pumps with the hand pump while the balloon is in the tunnel to aid in easier implant deployment. Once again, finger-sweep or direct visualization is used to confirm adequate pocket creation and the absence of soft-tissue bands that would impede placement of the implant. The implant is then prepared and introduced into the newly created pocket with the assistance of an insertion device. Closure The limited dissection technique preserves the CML5 in all directions except for the incision and inferior channel. This defect is closed by suturing the CML with interrupted 2-0 polydioxanone suture. The subcutaneous and dermal layers are closed in the usual fashion. Incisions are dressed with either surgical tape or glue. The patient is placed in a surgical bra. Data Collection/Statistical Methods All surgeons reported their collected data in a prespecified format in a shared secure online database. No patient identifying information was reported to the database. The operative and device characteristics were summarized using descriptive statistics for continuous variables and frequency counts and percentages for categorical variables. For the safety endpoints, qualitative descriptions were provided. For the patient satisfaction endpoints, a secure online survey, created by author consensus, was administered to patients at 3 months postprocedure by invitation from the respective operative surgeon, and surgeons recorded their own satisfaction scores in a secure online database following each case; both satisfaction measures were recorded on a 5-point Likert scale. Postoperative nipple-areola complex and breast sensation was evaluated postoperatively at 3 months via surgeon exam and subjective patient report. RESULTS A total of 161 female subjects were enrolled across five sites, but 2 were removed from the analysis due to age, as they were implanted off-label. Of note, the 2 patients removed were highly satisfied and had no complications. Mean age was 37 years (range, 22-71 years) (Table 1). Based on surgeon preference, some subjects underwent combined MI-BA with fat transfer and/or mastopexy (n > 22); however, the majority of patients (87%) enrolled with augmentation only. Over 95% of procedures were performed with the tumescent bolus technique rather than fanning (Table 2). Table 1.Patient DemographicsAge group (years)N% (N = 159)<303220%30-407346%>405434%Total159100%Mean age, 37 yearsRange, 22-71 years Patient Demographics Table 2.Surgical CharacteristicsAnesthesiaN% (N = 159) Local with sedation9358% Local96% General5736%Tumescent Bolus15195% Fanning85% Surgical Characteristics Most cases were performed using local anesthesia with light sedation (Table 2). Cases requiring general anesthesia mostly involved concomitant procedures, including mastopexy, liposuction, and/or abdominoplasty. Nearly 55% of the devices used were Motiva Ergonomix Demi projection; the remaining implants were Motiva Ergonomix Mini and Full profiles. The devices used were distributed evenly within the overall range of 150 to 315 cc (Table 3). Regarding postoperative complications at 3 months, there were no reports of hematoma, breast sensation issues, and/or pain. Three subjects experienced postoperative complications, described in Table 4, which included a single case of implant rippling, and a single case of early infection requiring an implant salvage procedure. This latter patient presented with breast erythema and was taken to the OR for washout and implant replacement. Cultures grew mycobacterium, but after infectious disease consult, it was believed to be a contaminant, and the patient was not treated with antibiotics. The patient went on to heal uneventfully. There was a single case of a high-riding implant at 3 weeks which resolved, with targeted unilateral implant massage, by the sixth postoperative week without further intervention. Table 3.Device CharacteristicsN% (N = 318)Device type Motiva Ergonomix Mini10332% Motiva Ergonomix Demi17254% Motiva Ergonomix Full4314%Device size (cc) 150-19510533% 200-24010332% 245-31511035% Device Characteristics Table 4.Postoperative Complicationsn%Winkling/rippling11%Breast sensation issue00%Nipple sensation issue00%Pain00%Hematoma00%Infection11%Malposition11% Postoperative Complications Ninety-six (96%) of the surgeons were satisfied or very satisfied (Table 5). Postoperatively, most subjects were satisfied or extremely satisfied with the overall look of their breasts after the procedure (94%) and the feel and movement of their breasts (98%). When asked if they would make the same decision to undergo the procedure again, 100% of patients responded positively. Most subjects learned about the procedure from either their surgeon or social media. Results from the patient survey are described in Tables 6 and 7 and Appendices A and B, available online at https://doi.org/10.1093/asj/sjag113. Table 5.Surgeon SatisfactionSurgeon responsen% (N = 159)Very satisfied14994%Satisfied32%Neither satisfied/dissatisfied32%Dissatisfied00Very dissatisfied00 Surgeon Satisfaction Table 6.Patient SatisfactionPatient responsen% (N = 90)How satisfied are you with the overall look of your breasts after the breast tissue preservation procedure? Extremely satisfied6673% Satisfied1921% Neutral56% Dissatisfied00 Very dissatisfied00How satisfied are you with the feel and movement of your breasts? Extremely satisfied7179% Satisfied1719% Neutral22% Dissatisfied00 Very dissatisfied00Would you make the same decision to undergo a breast tissue preservation procedure again? Yes90100% No00% Patient Satisfaction Table 7.Patient Preoperative and Recovery EvaluationsPatient responsen% (N = 90)How did you hear about minimally invasive breast augmentation? My surgeon4853.3% Social media4550.0% Friend or family55.6% Motiva website66.7% Influencer11.1% Other22.2%Able to go back to normal daily activity (driving, working, meeting with friends, etc)? 1-3 hours after surgery1517% 1 day after surgery3033% 3-5 days after surgery2831% 1 week after surgery1112% More than 1 week67%Did the breast tissue preservation procedure allow for minimal disruption to your lifestyle? Yes, it had minimal impact on my daily life6167.8% Mostly—some disruption by manageable2730.0% No, it disrupted my lifestyle more than I expected22.2% Not sure yet—still recovering00%How confident do you feel about your new breasts in daily life (eg, clothing, activities, intimacy)? Extremely confident6066.7% Confident2932.2% Neutral11.1% Slightly uneasy00% Not confident at all00% Patient Preoperative and Recovery Evaluations Follow-up is ongoing. The results are reported from an interim analysis with patients’ average time on the study after implantation being just short of 5 months (minimum, 2 months; maximum, 8 months). Figure 5—a 24-year-old female patient who underwent MI-BA with Motiva Ergonomix Demi 265-cc implants (courtesy of Jeremy Chidester, MD) and Figure 6—a 41-year-old female patient who underwent MI-BA with Motiva Ergonomix Demi 245-cc implants (courtesy of Kamakshi Zeidler, MD) feature 6-month surgical results, Figure 7—a 34-year-old female patient who underwent MI-BA with Motiva Ergonomix Mini 170-cc implants (courtesy of Troy A. Pittman, MD) features a 5-month surgical result. A 24-year-old female patient underwent minimally invasive breast augmentation with Motiva Ergonomix Demi 265-cc implants. (A, C) Preoperative and (B, D) 6 months postoperative. (Courtesy of Jeremy Chidester, MD.) A 41-year-old female patient underwent minimally invasive breast augmentation with Motiva Ergonomix Demi 245-cc implants. (A, C) Preoperative and (B, D) 6 months postoperative. (Courtesy of Kamakshi Zeidler, MD.) A 34-year-old female patient underwent minimally invasive breast augmentation with Motiva Ergonomix Mini 170-cc implants. (A, C) Preoperative and (B, D) 5 months postoperative. (Courtesy of Troy A. Pittman, MD.) DISCUSSION A growing trend in all surgical disciplines has been the move to more minimally invasive procedures. With this technique, we present a major shift away from traditional subpectoral augmentation techniques and toward tissue preservation–based methods that prioritize reduced tissue trauma, smaller incisions, quicker recovery, and less anesthesia. Many patients describe hesitancy about pursuing breast augmentation due to concerns of looking too overdone, concern over breast health, long downtime, implant safety, and the risk of undergoing general anesthesia. These and many other concerns help explain the reality that the number of breast augmentation procedures performed has been relatively stagnant over the past 30 years. Following the introduction of MI-BA, we are now consistently seeing patients who previously would never have considered breast augmentation. Market research suggests that 6 out of 10 women consider breast enhancement, but only 10% of these women move forward with the procedure.27 The breast implants used received FDA approval in late 202410 and the purposeful design of these implants, with a viscoelastic gel and shell and a surface that provides a soft capsule in all tissue planes, has provided the opportunity to develop procedures that take advantage of these attributes. Historically, subpectoral and dual-plane techniques were designed during the silicone implant moratorium era,6,15 when saline and earlier silicone implants required more soft-tissue coverage, making muscle coverage essential. It has been the authors, experience with these devices that they are able to perform well in the prepectoral plane, with less rippling and wrinkling, even with limited soft-tissue coverage.28 The defining feature of the technique is preservation of the native breast structures. Complete understanding of the breast anatomy and adoption of a standardized nomenclature is essential. By creating the implant pocket through hydrodissection, balloon expansion, and tissue elongation, the surgeon can preserve the attachments of the CML, ultimately preserving nerves, vascular structures, and native soft-tissue architecture. We must also emphasize that this is not a “subglandular” dissection where the implant abuts the corpus mammae, nor is it a “subfascial” dissection in which the pectoralis major fascia is lifted from the muscle. Confirming positioning in the intralamellar space under ultrasound guidance assures the surgeon that there is no breast tissue left behind the implant and that the implant is sequestered from the contaminated tissue of the corpus mammae, creating a stable relationship between the implant and the breast. The authors collectively agree that the learning curve for this technique is relatively short. From a technical standpoint, the procedural steps are straightforward, intuitive, and generally reproducible. However, hands-on experience is essential to mastering key aspects of the procedure, including tactile feedback during tissue expansion and pocket development. Other key challenges include ultrasound-guided pocket creation, tactile and visual understanding of hydrodissection, implant deployment through narrow access tunnels, and refined implant planning. Implant selection and proper implant placement is likely the most challenging aspect, and arguably the most important component for an optimal outcome. Rather than globally making the breast larger, this technique allows selective placement of the implant where tissue is deficient and capitalizes on tissue recruitment in the areas where tissue exists. This avoids adding volume to the breast where it is not needed, leading to a superior aesthetic result and ultimately a lighter breast. To properly evaluate the patient using this concept, the surgeon presses on the apex of the breast, displacing the tissue radially. That displacement mimics the effect on the implant. For patients with ample lower and lateral glandular tissue, a narrower implant can be placed selectively in the upper, inner quadrant. For patients with very little native breast tissue, a wider implant should be utilized to retore volume globally. When comparing implant selection with conventional breast augmentation, MI-BA aims to utilize narrower, more projecting implants in most cases. The demonstration of this concept can be seen in Video 1. It should be noted that, due to the nature of the procedure, sizers cannot be used intraoperatively. Implant selection should be finalized in the preoperative process. Virtual imaging and/or sizing systems can be utilized preoperatively to aid in patient communication at the surgeon's discretion. Precise placement is achieved with the balloon handle for control of the vertical and horizontal position of the balloon which allows accurate dissection and pocket creation. It is particularly valuable regarding breast asymmetry, for patients wanting upper pole fullness without a significant increase in volume, for patients with borderline ptosis but unwilling to undergo a breast lift, and for tight lower pole/tuberous breasts. The five major steps of the procedure—namely, (1) instillation of tumescent solution, (2) channel separation, (3) balloon expansion and tissue elongation, (4) implant insertion, and (5) closure—can be seen in Video 3, available online at https://doi.org/10.1093/asj/sjag113. A small number of the cases reported involved MI-BA with mastopexy. The augmentation portion of the technique is performed in an identical manner through an inframammary incision. The balloon dissector is deployed at the desired vertical height of the new breast mound. A “skin-only”–type mastopexy is performed with either a superior, central mound or superomedial pedicle, with attention given to avoid disruption of the posterior layer of the superficial fascia of the breast. Limited soft-tissue undermining and preservation of the CML (which houses the dominant vasculature) assists in maintaining sensation, as well as blood supply to the breast and the nipple-areolar complex. The lower central portion of breast tissue and/or a horizontal wedge of tissue at the IMF can be resected to aid in the prevention of future glandular ptosis. (Figure 8 shows MI-BA with mastopexy and Motiva Ergonomix Demi 230 cc implants at 5.5 months postoperation—courtesy of Troy A. Pittman, MD.) A 40-year-old female patient underwent minimally invasive breast augmentation with Motiva Ergonomix Demi 230-cc implants with simultaneous mastopexy. (A, C) Preoperative and (B, D) 5.5 months postoperative. (Courtesy of Troy A. Pittman, MD.) Only 1 of the authors in the study performed MI-BA combined with fat transfer (either autologous or injectable structural adipose filler derived from purified, sterilized human donor tissue). Indications for fat grafting (allograft or autograft) were primarily based on the patient's desire to modify their breast footprint, such as adding medial volume for patients with widely spaced breasts or in cases of pectus carinatum. In the minority of cases fat transfer was used to add soft-tissue coverage for very low-BMI patients with poor-quality tissue. A total of 15 to 30 mL of allograft or autograft per breast was the typical volume used for hybrid MI-BA and fat grafting cases. In the authors’ experience MI-BA decreases the need for fat transfer solely to avoid implant visibility compared to traditional breast augmentation techniques. The need for less soft-tissue coverage using MI-BA is likely threefold, accounted for by: the precise pocket control with the balloon inflation technique; the avoidance of cautery which may contribute to thinning of overlying soft-tissue coverage using conventional techniques; and the recruitment of better soft-tissue coverage by pushing the tissue up around the borders of the implant rather than conventional cutting techniques. It is worth noting that fat grafting solely to avoid implant visibility and wrinkling decreased over time as familiarity with these concepts increased. Regarding postoperative recovery, patients are advised to limit their activity (arm extension and heavy lifting) for 72 hours. Patients can return to light workouts after 10 days and all normal activity at 3 weeks. Patients are placed into a surgical bra postoperatively and we do not recommend breast banding. Should a patient present with a “high-riding” implant at 1 week, a superior breast band for a limited time and/or unilateral targeted implant massage is recommended. We do not recommend routine postoperative antibiotics. With any technique in which implants are placed in the prepectoral plane, there is a question regarding breast imaging. There are numerous imaging modalities to assist in early breast cancer detection. Historically, subpectoral implant imaging with mammography has been considered superior to examination of prepectoral implants.29 However, a recent systematic analysis suggests that breast cancer prognosis of patients undergoing breast augmentation is unaffected by implant location.30 It is important to recognize that in dual-plane augmentation, the lower half of the breast is often subglandular and not truly submuscular. Thus, for all breast implants, bimodal or multimodal techniques should be considered to assist in early detection, including palpation, mammography, ultrasound, MRIs, and new emerging technologies such as molecular breast imaging.31 Bimodal evaluations have significantly improved early detection. Of importance, the minimally invasive technique places implants in the intralamellar space, which situates the implant on the pectoralis fascia but under the posterior lamella of breast tissue, and with this implant positioning, no breast tissue is left under the implant.16 Relative contraindications to this procedure include patients with a significant breast asymmetry, for which the use of sizers would be helpful. Additionally, it is important to keep in mind that, given the nature of the procedure, there is little ability to change or manipulate the IMF. Therefore, patients with a very short nipple-to-fold distance (<5-6 cm) who refuse mastopexy, and may need the IMF lowered, are generally not ideal candidates. A full list of relative contraindications can be found in Supplemental Figure 2, available online at https://doi.org/10.1093/asj/sjag113. Limitations The primary objective of this study was to describe the surgical technique of MI-BA, share clinical insights, and report early outcomes from a group of experienced surgeons. However, this series reflects an early experience, limited to a 6-month observation period, using a sixth-generation implant in conjunction with this minimally invasive approach. As a result, long-term clinical, aesthetic, and safety outcomes cannot yet be fully characterized. Continued follow-up is essential to assess durability, complication rates, and sustained patient satisfaction over time. Importantly, this patient cohort will remain under longitudinal surveillance and will serve as the basis for future publications focused on long-term outcomes. CONCLUSIONS MI-BA represents a paradigm shift in aesthetic breast surgery, enabled by modern implant technology and centered around atraumatic tissue preservation rather than sharp dissection. Although continued evaluation and validation of this approach are necessary, early observations suggest potential improvements in patient experience and recovery, with added benefits for both patients and surgeons. This approach allows breast augmentation to be performed under local anesthesia, minimizes disruption of native breast structures, and supports a more rapid postoperative recovery. This case series represents an early US experience utilizing sixth-generation silicone implants within a minimally invasive framework and provides a foundation for further investigation as adoption of this technique evolves. Supplemental Material This article contains supplemental material located online at https://doi.org/10.1093/asj/sjag113. Supplementary Material